Related Experiment Video
Updated: Aug 10, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
Design, synthesis, and biological activity of novel oxazole-based small molecule allosteric GLP-1R agonists
Ruifeng Wang1, Qing Liu2, Chaoyu Lu2
1School of Pharmacy, Shanxi Medical University, Taiyuan, 030001, China; Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.
Abstract:
Glucagon-like peptide-1 receptor is a key target for type 2 diabetes, but current peptide agonists suffer from low oral bioavailability and poor adherence, highlighting the clinical significance of developing small-molecule modulators. Starting from the lead compound V-0219, a series of novel oxazole-containing small-molecule positive allosteric modulators of GLP-1R were designed and synthesized via a scaffold hopping strategy. Systematic structure-activity relationship studies led to the identification of compound 5b, which exhibited superior GLP-1R potentiating activity (44.8% at 10 μM) compared to the lead. Mechanistic studies demonstrated that 5b enhances GLP-1(7-36)- and GLP-1(9-36)-induced cAMP accumulation, directly binds to and stabilizes the GLP-1R protein, and exerts glucose-lowering effects in a GLP-1R-dependent manner. In oral glucose tolerance tests in hGLP-1R knock-in mice, 5b demonstrated modestly improved glucose-lowering efficacy compared to V-0219. In addition, 5b exhibited lower cytotoxicity, favorable metabolic stability in mouse liver microsomes and plasma, and acceptable oral exposure. Collectively, 5b, as a lead compound for orally available small-molecule GLP-1R modulators, warrants further investigation and holds promise for the treatment of type 2 diabetes and related metabolic disorders.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.